(ASX:BOT) Botanix Pharmaceuticals Limited is a clinical stage synthetic cannabinoid company based in Perth (Australia) and Philadelphia (USA) committed to the development of pharmaceutical products that are underpinned by science and supported by well-controlled randomised clinical trials.
Technicals: Shaping up to GAP
- Ascending Triangle Pattern
- 10/20 MA Golden Cross
- RSI Bullish + Above the 50
- MACD Bullish and Spread
- Fractal Target 1 lining up with Previou EQ and 0.236 Fib Retracement @ 0.081
- Fractal Target 2 close to another Resistance level @ 0.095
- GAPs Present @ 0.14 - 0.234, 0.027 - 0.029, 0.034 - 0.037
- "Golden Pocket" 0.5-.618 Fib Retracement sitting within 0.14 - 0.234 GAP
- Stop loose @ 0.042
Fundamentals: Undervalued, Debt Free, +$20 Million Cash
- Multiple Phase 2 Clinical Trials underway with FDA Meetings successful for there Cannabinoid Products.
- Antimicrobial Study Phase 2 to be completed 4th Quarter 2020
- World Class Board of Directors & Advisors with Key Experience in Management, Research & Development, FDA Approvals, Pharmaceuticals, Therapeuticals
- Debt Free with $24.6 Million in Cash and Investments
- Total Liabilities of $1.37 Million covered by $24.7 Million in Assets
Technically and Fundamentally this is shaping up to be a great Trade & Long term Investment. My only Concern is how the effects of COVD19 will weigh on the Therapeutic/ Pharmaceutical Industry.
Definitely a Sector and Company to keep watch of.
Setups/Strategies should be based on Individual Trade/ Risk Management Plan
These Ideas are NOT 'Financial Advice'!. Scenarios are based off a mixture of TA and Fundamentals current at the time. All IMO GLTAH. Happy Hunting!!!
Technicals: Shaping up to GAP
- Ascending Triangle Pattern
- 10/20 MA Golden Cross
- RSI Bullish + Above the 50
- MACD Bullish and Spread
- Fractal Target 1 lining up with Previou EQ and 0.236 Fib Retracement @ 0.081
- Fractal Target 2 close to another Resistance level @ 0.095
- GAPs Present @ 0.14 - 0.234, 0.027 - 0.029, 0.034 - 0.037
- "Golden Pocket" 0.5-.618 Fib Retracement sitting within 0.14 - 0.234 GAP
- Stop loose @ 0.042
Fundamentals: Undervalued, Debt Free, +$20 Million Cash
- Multiple Phase 2 Clinical Trials underway with FDA Meetings successful for there Cannabinoid Products.
- Antimicrobial Study Phase 2 to be completed 4th Quarter 2020
- World Class Board of Directors & Advisors with Key Experience in Management, Research & Development, FDA Approvals, Pharmaceuticals, Therapeuticals
- Debt Free with $24.6 Million in Cash and Investments
- Total Liabilities of $1.37 Million covered by $24.7 Million in Assets
Technically and Fundamentally this is shaping up to be a great Trade & Long term Investment. My only Concern is how the effects of COVD19 will weigh on the Therapeutic/ Pharmaceutical Industry.
Definitely a Sector and Company to keep watch of.
Setups/Strategies should be based on Individual Trade/ Risk Management Plan
These Ideas are NOT 'Financial Advice'!. Scenarios are based off a mixture of TA and Fundamentals current at the time. All IMO GLTAH. Happy Hunting!!!